WBB Securities rated Strong Buy Omeros Corporation (NASDAQ: OMER) on 08/18/2015. Previously WBB Securities rated Buy Omeros Corporation (NASDAQ: OMER) on 10/26/2009., when the stock price was $6.58. Since then, Omeros Corporation has gained 139.51% as of 01/26/2016's recent price of $15.76.
If you would have followed the previous WBB Securities's recommendation on OMER, you would have gained 139.51% of your investment in 2283 days.

Omeros Corporation is a clinical-stage biopharmaceutical company engaged in discovering, developing and commercializing products focused on inflammation and disorders of the central nervous system. The Company?s clinically advanced product candidates are derived from its PharmacoSurgerytm platform designed to improve the clinical outcomes of patients undergoing arthroscopic, ophthalmological, urological and other surgical and medical procedures. Its PharmacoSurgery platform is based on low-dose combinations of therapeutic agents delivered directly to the surgical site throughout the duration of the procedure to preemptively inhibit inflammation and other problems caused by surgical trauma and to provide clinical benefits both during and after surgery.

Research from WBB Securities provides investment professionals with up-to-date, in-depth, accurate and insightful reporting of companies that specialize in biotechnology, medical devices and healthcare. Our goal is to provide independent, straight-forward and up-to-date research so you can make educated decisions about your investments.

Marked as spam